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Abstract
CD4+CD25+ regulatory T lymphocytes (TR) constitute 5–10% of peripheral CD4+ T cells in naive
mice and humans, and play an important role in controlling immune responses. Accumulating
evidences show that TR cells are involved in some physiological processes and pathologic conditions
such as autoimmune diseases, transplantation tolerance and cancer, and might be a promising
therapeutic target for these diseases.
To evaluate the change of CD4+CD25+ TR cells in mouse tumor models, CD4+CD25+ subset in
peripheral blood and spleen lymphocytes from normal or C26 colon-carcinoma-bearing BABL/c
mice were analyzed by flow cytometry using double staining with CD4 and CD25 antibodies.
The proportion of CD4+CD25+/CD4+ in spleen lymphocytes was found to be higher than that in
peripheral blood lymphocytes in normal mice. No difference was observed in the proportion in
peripheral blood lymphocytes between tumor bearing mice and normal mice, while there was a
significant increase in the proportion in spleen lymphocytes in tumor bearing mice as compared
with normal mice. Moreover, the proportion increased in accordance with the increase in the
tumor sizes. The increase in the proportion was due to the decrease in CD4+ in lymphocytes,
which is resulted from decreased CD4+CD25- subset in lymphocytes. Our observation suggests
the CD4+CD25+/CD4+ proportion in spleen lymphocytes might be a sensitive index to evaluate
the TR in tumor mouse models, and our results provide some information on strategies of
antitumor immunotherapy targeting CD4+CD25+ regulatory T lymphocytes.
Background
Early in 1970s, the concept of suppressor T cells was devel-
oped and it was envisioned that this subset of lym-
phocytes was responsible for the active control, and
ultimately the termination, of immune responses [1]. But
the characters of this subset had not been well studied
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mainly because its distinct phenotype was not identified.
In 1990s, Sakaguchi et al found that a subset of CD4+
lymphocytes in peripheral blood of normal mice
expressed the IL-2R-α (CD25) and it down-regulated the
immune response to self and non-self antigens [2]. Soon
the CD4+CD25+ lymphocytes were verified as one group
of suppressor T cell and termed as thymic derived "natu-
rally occurring" regulatory T cells (TR). TR represents a
minor (5–10%) component of peripheral CD4+ T cells
but plays an important role in controlling immune
responses [3]. Accumulating evidences show that TR cells
possess potent suppressive activity both in vivo and in
vitro and are involved in autoimmune diseases, transplan-
tation tolerance and tumor immunity [2-5]. The transfer
of CD4+CD25- cells into nude mice resulted in autoim-
mune diseases; reconstitution of CD4+CD25+ cells after
transfer of CD4+CD25- cells prevented the development
of autoimmunity [2]. Similarly, depletion of these cells
induced gastritis and late-onset diabetes [6], impaired
development or dysfunction of these cells increased sus-
ceptibility to experimental autoimmune encephalomyeli-
tis [7], multiple sclerosis [8] and other autoimmune
diseases [9,10]. Conversely, an increased percentage of
CD4+CD25+ TR cells in total CD4+ T cells was found in
peripheral blood of cancer patients [11-14] and depletion
of CD25+ cells alone or combination with other strategies
might cause tumor regression [4,15,16]. All these studies
indicated the importance of TR  cells in controlling
immune response. The mechanism of how the TR cells
control immune response is still unclear. Previous studies
show that activated TR cells strongly inhibit proliferative
responses of CD4+ or CD8+ T cells in vitro [17,18], more-
over, it down-regulates co-stimulatory molecules on den-
dritic cells (DC) [19], inhibit the maturation and antigen-
presenting function of DC [20], and suppress activated
and matured DC driven responses [21]. The important
role of TR cells in immunoregulation makes it be recog-
nized as an attractive therapeutic target for immune-
related diseases.
In our animal experiments of antitumor immunotherapy
that targeting CD4+CD25+ TR cells, to our surprise, we did
not find an increase of CD4+CD25+/CD4+ in peripheral
blood of tumor bearing BALB/c or C57BL/6 mice, this is
not in accordance with the increase of the proportion in
cancer patients as reported by Wolf et al [11]. In order to
find a way to evaluate the CD4+CD25+ TR cells in tumor-
bearing mice, we analyzed CD4+CD25+ subset in periph-
eral blood and spleen lymphocytes from normal or C26
colon-carcinoma-bearing mice by flow cytometry.
Methods
Mice and tumor model
6 to 8 weeks BALB/c mice were purchased from the Labo-
ratory Animal Center of Sun Yet-sen University. Mouse
C26 colon carcinoma cell line was a gift from Prof. Li-Jian
Xian (Cancer Center, Sun Yet-sen University). The C26
Cells were cultured in RPMI 1640 medium (Gibco
Invitorogen Corporation) supplemented with 10% fetal
calf serum (FCS; Gibco Invitorogen Corporation,
Carlsbad, CA), 100 U/ml of penicillin G and 100 µg/ml of
streptomycin, and the medium was renewed every 2 to 3
days. After growing to confluency, the cells were detached
with trypsin-EDTA, resuspended in serum-free RPMI 1640
medium and inoculated subcutaneously at right axilla
with 1 × 105 to 1 × 107 live tumor cells per mouse.
Reagents
PE-conjugated anti-mouse CD4, Cychrome-conjugated
anti-mouse CD25 antibodies were purchased from eBio-
science. Red blood cell lysis buffer is composed of 0.155
M ammonium chloride, 0.01 M potassium bicarbonate,
and 0.1 mM EDTA. Fixation solution contains 1% para-
formaldehyde in PBS.
Samples preparation and flow cytometry
Mouse peripheral blood was collected from orbital plexus
and anticoagulated with 20 U/ml sodium heparin. Single-
cell suspensions of splenocytes were prepared by grinding
the spleen with the plunger of a disposable syringe, pass-
ing the ground spleen through nylon mesh, and suspend-
ing the cells in PBS. Mouse peripheral blood or spleen
single-cell suspensions were stained with PE-conjugated
anti-mouse CD4 and Cychrome-conjugated anti-mouse
CD25 antibodies at 4°C for 30 minutes. Then, erythro-
cytes were lysed by red blood cell lysis buffer. After wash
with PBS, the samples were fixed with fixation solution
and analyzed on a FACScalibur™ flow cytometer (BD Bio-
sciences) with CELLQuest™ software.
Statistical Analysis
The data are summarized as the mean ± standard error.
Statistical analysis was performed using the Student t test,
statistical significance was accepted at the P < 0.05 level.
Results
CD4+CD25+/CD4+ in peripheral blood and spleens from 
normal BALB/c mice
To evaluate the normal proportion of CD4+CD25+/CD4+
in mice, 6 to 8 weeks normal BALB/c mice (n = 10) were
sacrificed to test the proportion in spleen and peripheral
blood lymphocytes by flow cytometry using anti-mouse
CD4 and CD25 antibodies. The total CD4+ lymphocytes,
CD4+CD25+ subset, and CD4+CD25+/CD4+ in spleen or
peripheral blood lymphocytes were shown in Table 1. In
normal mice, the CD4+CD25+ TR cells appear in spleen or
peripheral blood in a relative stable percentage manner.
The proportion of CD4+CD25+/CD4+ in peripheral
blood was 6.19 ± 0.86%, which is in accordance with the
results reported by others [3]. Otherwise, theJournal of Translational Medicine 2005, 3:5 http://www.translational-medicine.com/content/3/1/5
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CD4+CD25+/CD4+ proportion in spleen was higher than
that in peripheral blood (10.23 ± 1.88% vs 6.19 ± 0.86%,
P < 0.001). And, the higher level of the proportion in
spleen is due to a lower level of the total CD4+ lym-
phocytes (CD4+CD25+ plus CD4+CD25-) in spleen than
that in peripheral blood (37.06 ± 5.76 vs 56.80 ± 6.38, P
< 0.001). The representable figures of peripheral blood
and spleen lymphocytes double stained with CD4 and
CD25 antibodies were shown in Figure 1.
CD4+CD25+/CD4+ in peripheral blood and spleens from 
C26 tumor-bearing BALB/c mice
To investigate the possible changes of the proportion in
tumor bearing mice, 1 × 105 to 1 × 107 live C26 colon car-
cinoma cells were inoculated subcutaneously at right
axilla of BALB/c mice respectively (n = 12). 20 days later,
tumor nodules were formed at different sizes from 7 to 40
mm in diameters. The mice were sacrificed and peripheral
blood and spleen lymphocytes were prepared for double
staining with anti-mouse CD4 and CD25 antibodies. In
peripheral blood, we did not find an increase in
CD4+CD25+/CD4+ in tumor bearing mice, compared
with that in normal mice. Otherwise, an increased propor-
tion of CD4+CD25+/CD4+ in spleen lymphocytes was
observed in tumor bearing mice, moreover, the propor-
tion increased in accordance with the increase in tumor
sizes, as shown in Figure 2A. The representable double
staining figure of peripheral blood or spleen lymphocytes
from tumor bearing mice were shown in Figure 2B–C.
Considering the short tumor bearing duration, we
Table 1: The percentages of CD4+CD25+ and CD4+, and the proportions of CD4+CD25+/CD4+ in peripheral blood and spleen 
lymphocytes from normal BALB/c mice.
CD4+ CD4+CD25+ CD4+CD25+/CD4+ total lymphocyte
peripheral blood (n = 10) 56.80 ± 6.38 3.50 ± 0.45 6.19 ± 0.86 6.73 ± 0.84 (109/L)
spleen (n = 10) 37.06 ± 5.76 3.79 ± 0.93 10.23 ± 1.88 1.54 ± 0.23 (× 108)
P value <0.001 0.38 <0.001 -
The proportions of CD4+CD25+ subset in peripheral blood and spleen lymphocytes from normal BALB/c mice Figure 1
The proportions of CD4+CD25+ subset in peripheral blood and spleen lymphocytes from normal BALB/c mice. Mouse periph-
eral blood (A) or spleen single-cell suspensions (B) were collected or prepared, and stained with PE-conjugated anti-mouse 
CD4 and Cychrome-conjugated anti-mouse CD25 antibodies, after the lysis of erythrocytes, the samples were analyzed by 
flow cytometry.Journal of Translational Medicine 2005, 3:5 http://www.translational-medicine.com/content/3/1/5
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prolonged the observation to 50 to 60 days, the increase
in the proportion was not yet observed in peripheral
blood (data not shown).
The changes of the percentages of CD4+CD25+, 
CD4+CD25- and total CD4+ cells in spleen lymphocytes 
from tumor bearing mice
The proportion of CD4+CD25+/CD4+ was determined by
two factors: CD4+CD25+ in lymphocytes (numerator)
and total CD4+ in lymphocytes (denominator). The
increase of the proportion may be due to the increase of
CD4+CD25+ subset or decrease of CD4+ subsets, or both.
To investigate the possible reason that the proportion
increased in spleen lymphocytes of tumor-bearing mice,
we analyzed the CD4+CD25+ and total CD4+ cells in
spleen lymphocytes. We found there was no obvious
change in CD4+CD25+ in spleen lymphocytes from
tumor bearing mice, otherwise, a decrease in total CD4+
lymphocytes was found with the increase of the tumor
sizes, and the decrease was mainly due to the decrease of
CD4+CD25- subset, as shown in Figure 3 and Figure 2C.
The relationship between tumor sizes and the CD4+CD25+/ CD4+ proportions in peripheral blood or spleen lym- phocytes in tumor bearing mice Figure 2
The relationship between tumor sizes and the CD4+CD25+/
CD4+ proportions in peripheral blood or spleen lym-
phocytes in tumor bearing mice. (A) 1 × 105 to 1 × 107 C26 
colon carcinoma cells were inoculated subcutaneously at 
right axilla of BALB/c mice (n = 12). 20 days later, after 
tumor sizes were measured, the mice were sacrificed and 
peripheral blood lymphocytes (❍ ) and spleen (■ ) lym-
phocytes were stained with anti-mouse CD4 and CD25 anti-
bodies. x-axis represents the diameters of tumors; y-axis 
represents the proportion of CD4+CD25+/CD4+. The 
absolute total lymphocyte counts were 9.85 ± 2.34 (× 109/L) 
in peripheral blood and 2.37 ± 0.77 (× 108) in spleen. The 
representative figures of CD4+CD25+ subset in peripheral 
blood (B) or spleen (C) lymphocytes from tumor bearing 
mice were also shown.
The relationship between tumor sizes and the percentages of  total CD4+ (■ ), CD4+CD25- () or CD4+CD25+ (❍ ) cells  in spleen lymphocytes in tumor bearing mice Figure 3
The relationship between tumor sizes and the percentages of 
total CD4+ (■ ), CD4+CD25- () or CD4+CD25+ (❍ ) cells 
in spleen lymphocytes in tumor bearing mice. Samples were 
prepared and analyzed as in Figure 2, x-axis represents the 
diameter of tumors; y-axis represents the percentages in 
spleen lymphocytes.Journal of Translational Medicine 2005, 3:5 http://www.translational-medicine.com/content/3/1/5
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Discussion
The identification of CD4+CD25+ as the phenotype of
regulatory T lymphocytes is one of the highlights of recent
immunological progress. These cells are proven to be
involved in autoimmune diseases, transplantation toler-
ance and tumor immunity, etc [3]. The relationship
between cancer and immune system has been studied and
debated for a long time, now we know that immunodefi-
cient or immunosuppressed humans or animals show
greater incidences of cancer [22]; at the same time,
immune function in cancer patients are often compro-
mised by tumor itself or related treatment, and this often
leads patients to disadvantageous situation. To restore the
immune function in cancer patients is an important
element in cancer treatment. The identification of
CD4+CD25+ TR cells provided a new way to study rela-
tionship between tumor development and immune sup-
pression. A higher proportion of CD4+CD25+ TR cells was
found in peripheral blood of cancer patients and to be
related to poor prognosis of the diseases [11,12]. Deple-
tion of CD4+CD25+ TR cells using anti-CD25 mAb could
promote anti-tumor immunity [4,15,16]. All these indi-
cated that CD4+CD25+ TR cells maybe an attractive target
to restore or improve immune function in cancer
treatment.
In our animal experiments of antitumor immunotherapy,
we did not find an increase of CD4+CD25+/CD4+ in
peripheral blood in tumor bearing BALB/c mice, this is
not in accordance with the results in cancer patients
reported previously [11]. To find a way to evaluate the
CD4+CD25+/CD4+ in antitumor immunotherapy target-
ing CD4+CD25+ TR cells, we analyzed the proportion in
peripheral blood and spleen lymphocytes in normal or
C26 colon-carcinoma-bearing mice by flow cytometry. In
present study, the proportion of CD4+CD25+/CD4+ in
peripheral blood of normal mice was about 6.19%, which
was compatible with the results reported previously (5–
10%). But in spleen lymphocytes from normal mice, we
found a higher proportion of CD4+CD25+/CD4+
(around 10%), and the higher proportion is due to a
lower level of total CD4+ lymphocytes in spleen, com-
pared with that in peripheral blood, whereas the percent-
ages of the CD4+CD25+ cells are similar.
In C26-colon-carcinoma bearing BALB/c mice, we found
an increase of CD4+CD25+/CD4+ in spleen but not in
peripheral blood, furthermore, the proportion in spleen
lymphocytes increased with the increase of tumor sizes.
The phenomenon that the increase of the proportion in
spleen separates with that in peripheral blood may be due
to: 1). Spleen is a professional immune organ, which
maybe more sensitive to the changes of immune situation
than peripheral blood; 2). In this study, what we used is
artificial tumor model, not spontaneous tumor model,
and the tumor grew so quickly to cause mice moribund or
dead that the increase of the proportion did not appear in
peripheral blood. To observe the increase of the propor-
tion in peripheral blood of tumor bearing mice may need
a longer observation duration, or had better use spontane-
ous tumor models. In our experiments, we found the
increase of CD4+CD25+/CD4+ is due to the decrease of
CD4+ in lymphocytes, which is the result of decreased
CD4+CD25- subset in lymphocytes. Our results support
the observations reported by Sasada [12], in which the rel-
ative increase in the proportion of CD4+CD25+ T cells in
patients with gastrointestinal malignancies are due to a
selective reduction in the number of CD4+CD25- T cells.
A possible explanation for this is that CD4+CD25- subset
is more sensitive to clonal deletion or apoptosis than
CD4+CD25+ T cells [12,23,24]. Furthermore, it is possi-
ble that some factors, such as tumor-derived antigens or
molecules, can induce apoptosis selectively in the
CD4+CD25- subset but not in the CD4+CD25+ subset
[12].
The relationship between cancer and immune system has
been debated for a long time. Our results provided direct
evidence that the tumor might compromise the immune
function, since our tumor model was established on
BALB/c mice with normal immune function. It is known
that tumor cells secrete immunosuppressive cytokines
such as IL-10 and TGF-β [25-27], and the cytokines may
induce CD4+CD25- lymphocytes to convert to
CD4+CD25+ TR cells [28,29]. These all support the theory
that tumor may compromise the immune function.
Conclusions
In normal BALB/c mice, CD4+CD25+/CD4+ proportion
in spleen lymphocytes is higher than that in peripheral
blood lymphocytes. In C26-colon-carcinoma bearing
mice, no difference was found in the proportion in
peripheral blood lymphocytes compared with normal
mice; Otherwise, the proportion in spleen lymphocytes
obviously increased, moreover, the proportion increased
in accordance with the increase of tumor sizes. The
increase of the proportion is due to the decrease of total
CD4+ in lymphocytes, which is resulted from decreased
CD4+CD25- subset in lymphocytes. Our observation sug-
gest the CD4+CD25+/CD4+ proportion in spleen
lymphocytes might be a sensitive index to evaluate the TR
in tumor mouse models rather than that in peripheral
blood lymphocytes, and our results provide some infor-
mation on strategies of antitumor immunotherapy target-
ing CD4+CD25+ regulatory T lymphocytes.
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